

The PROCESS of NEW DRUG DISCOVERY and DEVELOPMENT

(SECOND EDITION)

Charles G. Smith, PhD; and James T. O'Donnell, PharmD, MS; Editors

TABLE OF CONTENTS

SECTION I: GENERAL OVERVIEW

Chapter 1: (Reprint) Introduction

By Charles G. Smith, PhD

Chapter 2: Overview of The Process of New Drug Discovery and Development, Second Edition

By Charles G. Smith, PhD; and James T. O'Donnell, PharmD, MS

Chapter 3: Integrated Product Development: From Lead Candidate Selection to Life-Cycle Management

By Madhu Pudipeddi, Abu T.M. Serajuddin, PhD; and Daniel Mufson, PhD

SECTION II: SCIENTIFIC DISCOVERIES APPLICATION IN NEW DRUG DEVELOPMENT

Chapter 4: Combinatorial Chemistry

By Michael H. Rabinowitz, PhD; and Nigel Shankley, PhD

Chapter 5: High-Throughput Screening: Enabling and Influencing the Process of Drug Discovery

By Carol Ann Homon, MS; and Richard M. Nelson, PhD

Chapter 6: Pharmacological And Pharmaceutical Profiling: New Trends

Part 1, by Joanne Bowes, PhD; Michael G. Rolf, PhD; and Jean-Pierre Valentin, PhD

Part 2, by Valérie Hamon, PhD; Mark Crawford, PhD; and Thierry Jean, PhD

Chapter 7: Cell-Based Analysis of Drug Response Using Moving Optical Gradient Fields

By Jeff M. Hall, PhD; Ilona Kariv, PhD; Patricia A. McNeeley; Phillip J Marchand; and Tina S. Nova, PhD

Chapter 8: Patient-Derived Primary Cells in High-Throughput Differential Anti-Tumor Screens: Let the Patients Be the Guide

By Irwin Braude, DSc

Chapter 9: The Evolving Role of the Caco-2 Cell Model to Estimate Intestinal Absorption Potential and Elucidate Transport Mechanisms

By Jibin Li and Ismael J. Hidalgo, PhD

Chapter 10: The Promise of Metabonomics in Drug Discovery

By Pauline Gee, PhD

Chapter 11: Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA-PWG-PhRMA-DruSafe Workshop

By Lawrence J. Lesko, PhD; Ronald A. Salerno, PhD; Brian B. Spear, PhD; Donald C. Anderson, MD; Timothy Anderson, PhD; Celia Brazell, PhD; Jerry Collins, PhD; Andrew Dorner, PhD; David Essayan, MD; Baltazar Gomez-Mancilla, MD, PhD; Joseph Hackett, PhD; Shiew-Mei Huang, PhD; Susan Ide, PhD; Joanne Killinger, PhD; John Leighton, PhD; Elizabeth Mansfield, PhD; Robert Meyer, MD; Stephen G. Ryan, MD; Virginia Schmith, PhD; Peter Shaw, PhD; Frank Sistare, PhD; Mark Watson, MD, PhD; and Alexandra Worobec, MD

Chapter 12: Drugs from Molecular Targets for CNS and Neurodegenerative Diseases

By William T. Comer, PhD; and Gönül Veliçelebi, PhD

Chapter 13: Safety Pharmacology

By Jean-Pierre Valentin, PhD

Chapter 14: Nonclinical Drug Safety Assessment

By Frederick E. Reno, PhD

Chapter 15: Preclinical Genotoxicity Testing—Past, Present and Future

By Richard H.C. San, PhD

SECTION THREE: STANDARD DRUG DEVELOPMENTAL ISSUES: UPDATED

Chapter 16: The Need for Animals in Biomedical Research

By Charles G. Smith, PhD

Chapter 17: Defining the Actual Research Approach to the New Drug Substance

By Charles G. Smith, PhD

Chapter 18:

By Sarfaraz K. Niazi, Ph.D.

- a) Good Pharmacokinetic Practice to Streamline New Drug Development
- b) Pharmacokinetic/Pharmacodynamic Modeling in New Drug Development

Chapter 19: Pharmaceuticals And Compounding Issues In New Drug Development And Marketing

By Loyd V. Allen, Jr., PhD

Chapter 20: Late Stage and Process Development Activities

By Charles Smith, PhD

SECTION FOUR: CLINICAL DEVELOPMENT

Chapter 21: Contract Research Organizations: Role and Function in New Drug Development

By F. Richard Nichol, Jr., PhD

Chapter 22: The Front Lines of Clinical Research: The Industry

By Lori Nesbitt, PharmD, MBA

Chapter 23: Horizons for Cancer Chemotherapy (and non-Chemotherapy)

By Daniel D. Von Hoff, MD, FACP

Chapter 24: Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) Clinical Testing Challenges

By Vincent Idemyor, PharmD

SECTION FIVE: REGULATORY AND LEGAL ISSUES AFFECTING DRUG DEVELOPMENT

Chapter 25: CTD: The Changing Face of the NDA

By Justina Molzon, MS Pharm, JD

Chapter 26: Electronic Publishing

By Heather Leigh Wallace

Chapter 27: The Important Role of Pharmacists in a Complex Risk Management System: Managing the Risks from Medical Product Use by Focusing on Patient Education, Monitoring, and Adverse Event Reporting

By Justina Molzon, MS Pharm, JD

Chapter 28: Liability, Litigation, and Lessons in New Drug Development

By James T. O'Donnell, PharmD, MS

Chapter 29: Problems in the Non-Drug Marketplace

By Stephen Barrett, MD

Chapter 30: Patents and New Product Development in the Pharmaceutical and Biotechnology Industries

By Henry Grabowski, PhD

Chapter 31: The Pharmaceutical Revolution: Drug Discovery and Development

By John C. Somberg, MD

SECTION SIX: CASE HISTORIES

Chapter 32: The Discovery of Rituxan

By Mitchell E. Reff, PhD

Chapter 33: Funding the Birth of a Drug: Lessons from the "Sell" Side

By Howard E. (Ted) Greene, Jr.

Chapter 34: Innovations for the Drug Development Pathway: What Is Needed Now

Janet Woodcock, MD

Chapter 35:

By Mark Paich, PhD; Corey Peck; Jason Valant, Kirk Solo

- a) **Using Dynamic Modeling to Assess and Maximize Commercial Potential of Developmental Drug Compounds**
- b) **Risk Assessment and Addressing Uncertainty in Pharmaceutical New Drug Discovery and Development**